Washington: Scientists have developed a new drug-discovery strategy, which will help them in rapidly selecting chemical compounds that will have a desired effect on cells.
Researchers from the Scripps Research Institute (TSRI) has also tried to highlight how these compounds will work.
Scientists have identified a compound that shows promise for treating obesity-linked diabetes by using the innovative technique, and were able to identify the fat-cell enzyme that the compound inhibits.
The strategy uses the increasing availability of special libraries of related compounds that act as inhibitors of entire enzyme classes.
The researchers have used a set of compounds, recently synthesized by Cravatt's laboratory, that tend to inhibit serine hydrolases.
The researchers have been able to use combined phenotypic screening and target-identification approach to quickly discover, characterize and carry out preclinical tests of a potential new drug for obesity-linked diabetes.
The study was published an advance online issue of Nature Chemical Biology.
